Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 2Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 699Lung Neoplasms 297Small Cell Lung Carcinoma 149Colorectal Neoplasms 113Melanoma 106Neoplasms 93Breast Neoplasms 93Ovarian Neoplasms 92Neoplasm Metastasis 85Squamous Cell Carcinoma of Head and Neck 83Stomach Neoplasms 81Pancreatic Neoplasms 78Carcinoma, Renal Cell 66Triple Negative Breast Neoplasms 63Esophageal Neoplasms 51Endometrial Neoplasms 48Uterine Cervical Neoplasms 47Head and Neck Neoplasms 47Mesothelioma 42Mesothelioma, Malignant 41Sarcoma 40Prostatic Neoplasms 36Urinary Bladder Neoplasms 34Carcinoma, Transitional Cell 32Colonic Neoplasms 31Carcinoma, Hepatocellular 31Adenocarcinoma of Lung 31Carcinoma 26Recurrence 21Thyroid Neoplasms 20

Interventions

cemiplimab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × Thoracic × Clear all
NCT05094804 2023-11-02

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

OncoResponse, Inc.

Phase 1/2 Unknown
172 enrolled
DermatologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Leiomyosarcoma, Liposarcoma, Melanoma, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡